215 related articles for article (PubMed ID: 18391611)
1. Erythropoietin-stimulating agents in oncology.
Savona MR; Silver SM
Cancer J; 2008; 14(2):75-84. PubMed ID: 18391611
[TBL] [Abstract][Full Text] [Related]
2. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
3. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
5. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
6. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
7. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
Locatelli F; Gascón P
Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
[TBL] [Abstract][Full Text] [Related]
8. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
9. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival.
Smith RE
J Support Oncol; 2003; 1(4):249-56, 258-9; discussion 257-8. PubMed ID: 15334867
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of anemia and erythrocytosis.
Hodges VM; Rainey S; Lappin TR; Maxwell AP
Crit Rev Oncol Hematol; 2007 Nov; 64(2):139-58. PubMed ID: 17656101
[TBL] [Abstract][Full Text] [Related]
12. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
13. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin therapy in cancer patients.
Doweiko JP; Goldberg MA
Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
Santini V
Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin: the swinging pendulum.
Oster HS; Neumann D; Hoffman M; Mittelman M
Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
[TBL] [Abstract][Full Text] [Related]
17. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
Katodritou E; Dimopoulos MA; Zervas K; Terpos E
Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
[TBL] [Abstract][Full Text] [Related]
18. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
19. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
Gebara SN; Moubayed H
J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.
Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W
Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]